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Ligand substitutions between ruthenium–cymene
compounds can control protein versus DNA
targeting and anticancer activity
Zenita Adhireksan1,*, Gabriela E. Davey1,*, Pablo Campomanes2,3,*, Michael Groessl4, Catherine M. Clavel2,
Haojie Yu5, Alexey A. Nazarov2,w, Charmian Hui Fang Yeo6, Wee Han Ang6, Peter Dro¨ge5, Ursula Rothlisberger2,
Paul J. Dyson2 & Curt A. Davey1
Ruthenium compounds have become promising alternatives to platinum drugs by displaying
speciﬁc activities against different cancers and favourable toxicity and clearance properties.
Nonetheless, their molecular targeting and mechanism of action are poorly understood. Here
we study two prototypical ruthenium-arene agents—the cytotoxic antiprimary tumour
compound [(Z6-p-cymene)Ru(ethylene-diamine)Cl]PF6 and the relatively non-cytotoxic
antimetastasis compound [(Z6-p-cymene)Ru(1,3,5-triaza-7-phosphaadamantane)Cl2]—and
discover that the former targets the DNA of chromatin, while the latter preferentially forms
adducts on the histone proteins. Using a novel ‘atom-to-cell’ approach, we establish the basis
for the surprisingly site-selective adduct formation behaviour and distinct cellular impact of
these two chemically similar anticancer agents, which suggests that the cytotoxic effects
arise largely from DNA lesions, whereas the protein adducts may be linked to the other
therapeutic activities. Our study shows promise for developing new ruthenium drugs, via
ligand-based modulation of DNA versus protein binding and thus cytotoxic potential, to target
distinguishing epigenetic features of cancer cells.
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M
etal-based compounds, such as cisplatin, carboplatin
and oxaliplatin, are among the most widely used
chemotherapeutic agents1,2. The therapeutic effect of
these classic platinum drugs is mediated by formation of DNA
lesions, which appear to interfere mainly with transcription
resulting in apoptosis. However, there is limited effectiveness due
to severe toxicity and intrinsic or acquired resistance issues3.
Indeed, the small size and square planar geometry of the platinum
species yields only modest site discrimination in reaction with the
double helix, with adducts forming preferentially at the most
solvent accessible guanine nucleotides4.
The limitations associated with traditional platinum agents and
improved knowledge of tumour biology has prompted renewed
interest in the development of alternative metal-based anticancer
compounds5. Ruthenium agents have been showing great
promise from their selective activity against speciﬁc cancer cells
types in combination with low toxicity, and two compounds are
presently in clinical trials6. Moreover, the octahedral bonding of
both Ru(II) and Ru(III) species affords an extensive repertoire
of three-dimensional architectures, giving the potential for a
high degree of site selectivity and implementation of favourable
pharmacological attributes. Nonetheless, relatively little is known
about the molecular targeting characteristics and mechanism of
action of ruthenium agents. Although it is traditionally assumed
that DNA is the pharmacological target, recent evidence suggests
that, at least for certain compounds, proteins are likely involved
in the therapeutic effect7–10. However, chemical attributes that
could distinguish the DNA versus protein targeting are not
known.
A caveat of many in vitro studies on the molecular targeting of
reactive metal species is that most can form adducts on isolated
guanine bases or oligonucleotides in solution, whereas in the cell
site selectivity is governed by the outcome of competition
between many different kinds of molecules. Moreover, the
packaging of the genome by histone proteins into nucleosomes
can alter the adduct formation potential of different DNA sites11.
We earlier found that the ruthenium antimetastasis agent
[(Z6-p-cymene)Ru(1,3,5-triaza-7-phosphaadamantane)Cl2]12,13
(RAPTA-C; Fig. 1) accumulates on cellular chromatin,
potentially forming adducts at speciﬁc histone sites on the
nucleosome core8. This suggested that RAPTA-C may primarily
target proteins, but it was unclear whether adduct accumulation
on chromatin in the cell was primarily associated with the
histone or the DNA component. Intriguingly, while RAPTA-C
is inactive against primary tumours, it is able to inhibit both the
spreading and growth of metastases in mice and also has anti-
angiogenic properties13,14. Indeed with its low cell-killing
potential, whereby growth inhibition assays of RAPTA-C have
yielded IC50 values of4300 mM for both normal and cancer cell
lines13, RAPTA-C would not be considered cytotoxic in
standard compound screening assays15.
In the present study, we established that the chromatin-bound
adducts in cancer cells treated with RAPTA-C are primarily
associated with the protein component, not the DNA. Since
related ruthenium compounds are believed to preferentially
target DNA, we wanted to determine whether this is the
case, and if so, to establish the basis for such differential
molecular discrimination. We found that [(Z6-p-cymene)
Ru(ethylenediamine)Cl]PF6 (refs 16,17) (RAED-C; Fig. 1a)
does preferentially target the DNA component of chromatin
in cells. In contrast to RAPTA-C, RAED-C displays high
cytotoxicity and antiprimary tumour activity analogous to that
of cisplatin, and we employed structural, computational and
analytical methodologies to understand the basis for the
surprisingly different activities of these two structurally related
ruthenium agents.
Results
Protein versus DNA targeting. We used inductively coupled
plasma mass spectrometry (ICP-MS) to characterize the locali-
zation of RAED-C and RAPTA-C in cancer cells (Table 1).
Subsequent to incubation of cells with the two agents at their
respective IC50 values (Table 2), B33 106 and B250 106
molecules of RAED-C and RAPTA-C, respectively, are taken up
per cell. Of the total intracellular ruthenium content, 8% for
RAED-C compared with 4% for RAPTA-C is associated with the
chromatin. Of these chromatin-bound adducts, the majority is
associated with the DNA component for RAED-C (B77%),
whereas for RAPTA-C, the majority (B61%) is associated with
the protein component (from ratios of DNA:chromatin adducts
in Table 1).
To shed further light on the proclivity of both agents to amass
adducts within the nuclei of cancer cells, we employed size
exclusion chromatography-ICP-MS to characterize reactivity
towards the nucleosome core—the basic element of histone-
packaged DNA. RAED-C and RAPTA-C both react rapidly with
nucleosome core particle (NCP) in solution to yield stable
adducts, with respective association constants of 6.7 105 and
2.3 105M 1 (Table 1). However, compared with RAPTA-C,
for which B85% of the adducts are associated with the histone
proteins, RAED-C reacts threefold faster with B71% of adducts
associated with the DNA. Effectively, the same site selectivity
difference between the two compounds is apparent over the
10-fold range of agent:NCP molar stoichiometry tested (Table 3),
indicative of a fundamental site preference distinction. In
addition, DNA adduct levels measured following cellular uptake
continue to increase in a linear or exponential manner at
concentrations well above the IC50 values of RAED-C and
RAPTA-C (Fig. 2), indicating an absence of site saturation for
DNA binding.
The protein versus DNA preference based on isolated
nucleosome core reactivity is in excellent agreement with the
cellular localization results. In fact, the slightly higher fraction of
both RAED-C and RAPTA-C adducts associated with the DNA
for the cellular chromatin analysis suggests a greater reactivity of
the protein-free, or linker, DNA that connects adjacent nucleo-
some core regions in the genome (see below)—a phenomenon
that has been found for platinum drugs and other types of small
molecules11,18.
DNA sequence and histone packaging modulate site selectivity.
Previous studies have shown that RAED-C forms adducts at
guanine bases of oligonucleotide DNA19,20 and that RAPTA-C
also binds to DNA12. However, since DNA structure, ﬂexibility,
sequence context and histone packaging can inﬂuence platinum
drug site selection4,21 as well as adduct formation by non-metal-
based compounds that also attack guanine N7 groups22, we
wanted to determine whether these factors also inﬂuence
ruthenium agent reaction. We had previously established a
DNA footprinting assay based on exonuclease digestion to
analyse platinum compound site selection and cross-link
generation for both the naked and nucleosomal states of the
double helix4,21. The enzyme digests a single strand of double
helical DNA in the 30–50 direction, and we found here that, like
for platinum lesions, digestion is also arrested on encountering
ruthenium compound adducts (Figs 1b and 3).
The nuclease digestion DNA footprint for naked DNA and
NCP treated with RAED-C reveals selective adduct formation
at guanine nucleotides, but with an apparent favouring of GG
dinucleotide sites suggesting a contribution of electrostatic
attraction in governing reactivity, as observed for simple metal
hydrates. Strikingly, however, the site selectivity of the naked
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compared with the nucleosomal state is dramatically different,
with most of the reactive sites on naked DNA being protected by
histone packaging. The only sites of substantial adduct formation
are within the last double helical turn at the termini and at
locations 1.5 and 2.5 double helical turns from the nucleosome
centre (SuperHelix Location (SHL) ±1.5 and SHL ±2.5).
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Figure 1 | Ruthenium compound site selectivity. (a) Chemical structures and nucleosomal adducts of RAPTA-C and RAED-C. X-ray structures of
adducted NCP are shown looking down the DNA superhelical axis, with the nucleosome pseudo-twofold axis running vertically (arrow). Histone
proteins are shown in blue (H3), green (H4), yellow (H2A) and red (H2B), and the two 145-nucleotide DNA strands are cyan and orange. RAPTA-C
and RAED-C adducts appear with space-ﬁlling representation (sites 1–4, histone associated; sites SHL ±1.5, DNA associated). (b) DNA structure
and sequence preference of adduct formation. Orange and black lettering for the DNA sequence designates regions where the minor as opposed to
the major groove, respectively, face inward towards the histone octamer in the NCP. Severe kinks at locations of DNA stretching around SHL ±2 or
±5 (magenta arrows) result in a shift in the histone-DNA register, depicted as a gap in the sequence. The footprinting analysis of naked and
nucleosomal DNA, shown in Fig. 3, is summarized with exonuclease stop sites depicted as arrowheads, adjacent to the terminal 30 nucleotide,
pointing towards the ruthenium adduct. Filled and open symbols correspond to very strong and moderate termination points, respectively.
Table 1 | Ruthenium compound-binding behaviour.
RAED-C RAPTA-C
Nucleosome core binding
Kinetic rate constant, min 1 0.219 0.076
Association constant, M 1 6.7 105 2.3 105
Fraction bound to DNA, % 70.8±9.6 14.9±3.9
Fraction bound to histones, % 29.2±9.6 85.1±3.9
Cellular localization
Total cellular uptake, pmol Ru/106 cells 54±3 415±73
Bound to chromatin, pmol Ru/106 cells (% of total) 4.5±1.2 (8.3) 17.2±2.1 (4.1)
Bound to DNA, pmol Ru per mg DNA (% of total) 530±160 (6.4) 1040±229 (1.6)
RAED-C, [(Z6-p-cymene)Ru(ethylenediamine)Cl]PF6; RAPTA-C, [(Z6-p-cymene)Ru(1,3,5-triaza-7-phosphaadamantane)Cl2].
Mean±s.d., n¼4.
RAPTA-C values in part from ref. 8.
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Moreover, although the two terminal digest arrest locations are
identical between the naked and nucleosomal states, this is not
the case for the SHL ±1.5 and ±2.5 regions, which display
elevated reactivity in the nucleosome and single nucleotide
differences in adduct location between the two states. This
indicates that histone packaging can generate hotspots for
ruthenium agent adduct formation as well as shift inherent
reactivity from one guanine to an adjacent base.
For RAPTA-C, it is difﬁcult to obtain a strong DNA footprint
because of its low intrinsic reactivity for the double helix (Figs 1b
and 3). In fact, a substantial portion of the material contains
RAPTA-C adducts at the DNA termini, yielding an undigested
145 bp fragment. However, as there are effectively no DNA
termini in vivo, this is an artefact that suggests a steric challenge
behind RAPTA-C adduct formation on the double helix.
Nonetheless, albeit weak, the RAPTA-C footprint shows similar
guanine site selectivity in comparison with that of RAED-C.
Notably, there is a single strong site of RAPTA-C adduct
formation aside from the termini, which occurs for the
nucleosomal state at SHL ±1.5—analogous to the strongest site
of adduct formation observed for RAED-C.
Nucleosome structure governs adduct formation. In a recent
X-ray crystallographic study of RAPTA-C binding to the NCP,
we identiﬁed three sites of speciﬁc adduct formation that entail
bivalent coordination to glutamate, histidine and lysine side
chains of the histone proteins8 (Fig. 1a). RAED-C treatment of
NCP crystals also results in adduct formation at two different
histone sites, one of which (site 2) is common to both agents, but
in contrast to RAPTA-C, adducts on the DNA are also observed
(Figs 1 and 4; Table 4; Supplementary Fig. 1). The DNA adducts
occur at two pseudo-symmetry-related locations, SHL ±1.5, and
entail monofunctional coordination to the 50-guanine N7 atom of
an AGG element (Fig. 4). The cymene and ethylenediamine
groups of RAED-C form extensive van der Waals contacts with
the bases to the 50 and 30 sides of the coordinating guanine as well
as with the sugar-phosphate backbone. In addition, a hydrogen
bond occurs between the O6 atom of the coordinating guanine
and the proximal amine group of the ethylenediamine ligand.
The carrier ligands of RAED-C in the guanine adducts appear
to form favourable interactions with the double helix, but the
conformation of the DNA around both adduct sites is in fact
dramatically different compared with the native NCP structure
(Figs 1b and 4). In untreated NCP crystals, the double helix
displays stretch distortions over SHL ±1.5 (ref. 23), which
renders the DNA susceptible to attack at these locations. DNA
stretching, characterized by elongation and overtwisting of the
double helix, is an intrinsic property of the nucleosome that is
inﬂuenced by DNA sequence and exogenous factors, such as
metal binding4,24,25. The extreme kinking and other deformations
associated with stretching over SHL±1.5 yield exceptional steric
access to the 50-guanine N7 groups of the AGG elements4.
Although these native-state conformations favour RAED-C
attack, they are incompatible with the adducted state since a
Table 2 | Cell growth inhibition values (lM).
Cisplatin RAED-C RAPTA-C
A2780
IC50 1.00±0.05 4.53±0.93 247±15
IC90 9.17±1.85 17.6±1.2 772±35
crA2780
IC50 14.0±0.3 6.8±0.3 507±38
IC90 26.4±0.6 17.9±0.3 933±58
Mean±s.d., n¼ 3.
Table 3 | Adduct formation in the nucleosome core.
Ratio % DNA % Histone
RAED-C 1:1 61.67 38.33
2:1 75.88 24.12
4:1 63.92 36.08
10:1 81.79 18.21
Average 70.8±9.6 29.2±9.6
RAPTA-C 1:1 13.77 86.23
2:1 10.76 89.24
4:1 14.86 85.14
10:1 20.05 79.95
Average 14.9±3.9 85.1±3.9
RAED-C, [(Z6-p-cymene)Ru(ethylenediamine)Cl]PF6; RAPTA-C, [(Z6-p-cymene)Ru(1,3,5-triaza-7-phosphaadamantane)Cl2].
Fraction of adducts that form on the DNA and histones at different compound:nucleosome molar stoichiometry (ratio).
Mean±s.d., n¼4.
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Figure 2 | DNA–metal adduct levels in treated A2780 cancer cells.
Arrows indicate IC90 values for RAPTA-C (green; 772mM), cisplatin (red;
9.2 mM) and RAED-C (blue; 17.6mM). The interpolated agent concentration
values for cisplatin (9.5±1.0mM) and RAED-C (16.3±1.6mM) that would
yield the same adduct levels corresponding to the IC90 for RAPTA-C are
within error equal to the respective IC90 values of the two agents (dashed
lines provide approximate frame; mean±s.d., n¼ 3).
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steric clash would occur between the ethylenediamine group and
the adenine base to the 50-side if there were not a conformational
rearrangement. The solution adopted is for the DNA stretching to
relocate to the alternative location around the SHL ±5 regions,
which allows the double helix at SHL ±1.5 to assume a
conformation compatible with the RAED-C adducts.
Interestingly, although the structures of the AGG elements are
very different between the two pseudo-symmetry-related SHL
 1.5 and SHL þ 1.5 halves in the native state, they become
nearly identical in the adducted state. This indicates an
intrinsically favoured adduct conﬁguration, which notably
entails a pronounced asymmetric base–base unstacking dis-
tortion relative to the 50-adenine that allows steric
accommodation of the ethylenediamine group.
Steric factors dictate the distinct reactivity. Although the
histone protein site discrimination of RAPTA-C and RAED-C is
similar, with both agents preferentially forming adducts on
glutamate, their very different DNA versus protein adduct
formation potential suggests that the ethylenediamine and
phosphaadamantane ligands are decisive in governing molecular
targeting. To understand the basis for this distinction, we
employed hybrid quantum mechanical/molecular mechanical
(QM/MM) calculations. This approach allowed us to study the
adduct formation process even for the nucleosome core system in
its entirety (B200 kDaþ solvent) by treating all residues, with the
exception of those directly involved in adduct formation, with the
relatively computationally inexpensive MM potential.
We started by performing QM calculations of the structures
and energetics associated with RAED-C and RAPTA-C reacting
at isolated amino acids and nucleotides corresponding to the
histone glutamate (site 2) and SHL ±1.5 DNA guanine sites
common to both agents (Supplementary Fig. 2) as indicated by
the crystal structure and DNA footprinting analyses. However,
this simpliﬁed system cannot explain the observed differences in
the adduct formation potential between RAED-C and RAPTA-C,
but suggests that the two compounds are electronically very
similar and that distinctions in site preference involve structural/
dynamic features of the macromolecular context.
We subsequently performed QM/MM calculations on the
reaction of RAED-C and RAPTA-C with the explicitly solvated
NCP (Fig. 5; Supplementary Fig. 3 and Supplementary Movies
1–4). Whereas the two compounds present a similar free energy
barrier of about 20 kcalmol 1 for their reaction with the histone
site, that associated with adduct formation on the DNA site is
roughly twofold higher for RAPTA-C compared with RAED-C
(Supplementary Fig. 3). The activation barrier for RAED-C
reaction with DNA is slightly lower than for the histone site, but
in either case proceeds via an associative mechanism resulting in
departure of the water ligand (Fig. 5).
Adduct formation mechanisms analogous to those for
RAED-C were found for the reaction of RAPTA-C with the
histone glutamate as well as the DNA guanine sites (Fig. 5).
However, in contrast to the accessible histone sites on the surface
of the nucleosome, steric constraints in the double helix pose an
obstacle towards accommodating both the cymene and phos-
phaadamantane ligands for the RAPTA-C adduct, and the
resulting high energy pseudo-pentacoordinated transition state
is reﬂected in the less favourable orientation that must be adopted
by the cymene ligand and increased length of the incipient Ru–N
adduct bond relative to the RAED-C transition structure (Fig. 5).
As a consequence of the steric obstacles, the activation barrier for
RAPTA-C binding to the DNA is increased considerably and the
stability of the ﬁnal adduct is diminished as well, giving rise to
both a kinetically and thermodynamically unfavourable free
energy proﬁle.
For the above calculations, we studied the reactions of the
mono-aquated states for both RAED-C and RAPTA-C. However,
RAPTA-C contains a second chloride leaving group and can thus
potentially undergo an additional aquation event to produce the
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Figure 3 | Exonuclease digest analysis reveals DNA–ruthenium adduct
formation proﬁles. DNA samples, consisting of either NCP (N) or the
corresponding naked DNA (D) treated with RAPTA-C or RAED-C, are
shown with purine sequencing standards (m). Numbers represent
nucleotide position relative to the nucleosome centre (black arrow),
green asterisks designate the locations of guanine nucleotides and
magenta arrows indicate regions of DNA stretching in the native (solid)
and RAED-C adducted (dashed) NCP structures.
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di-aquated state, but solution studies of RAPTA-C have shown
that the mono-aquated form is the most abundant species26. Here
we also ﬁnd with QM simulations that the mono-aquated form of
RAPTA-C is far more energetically favourable (by 17 kcalmol 1)
than the di-aquated species (Supplementary Fig. 4). Nonetheless,
we carried out QM calculations of RAPTA-C adducts at both
glutamate and guanine sites to compare the energetics between
the mono- and di-aquated reactant species (Supplementary
Fig. 5). Although the adduct stability for both the protein and
the DNA sites are increased by the corresponding substitution of
H2O in place of Cl with respect to the reaction of the
di-aquated species, the stability of the protein adduct is still more
favourable in either case. This further indicates that the steric
bulk of the phosphaadamantane ligand is the primary factor that
distinguishes the histone/DNA site selectivity behaviour between
RAPTA-C and RAED-C.
Distinct activities in cancer cells. Given the differences in site
selectivity between RAED-C and RAPTA-C, we conducted cel-
lular impact experiments in comparison with cisplatin to shed
light on how differences in molecular targeting and adduct
characteristics may give rise to the pharmacological distinctions
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Figure 4 | Crystal structure of RAED-C adducts on the DNA and histones in the nucleosome core. At top, the two symmetry-related DNA adduct
sites (magenta) are shown in comparison with the respective native NCP structure (cyan; models were superimposed with respect to the guanine bases
to which RAED-C coordinates and are shown with space-ﬁlling representation). Hydrogen bonding between the ethylenediamine ligands and adducted
guanine bases is indicated with dashed lines (middle). Site 4/40 of the histone adducts (bottom right) entails binding along the pseudo-twofold axis
of the nucleosome (black arrow), coinciding with a crystallographic mixture of monofunctional binding to glutamate 41 of either copy of H2A.
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between these three compounds. We treated standard and cis-
platin-resistant human ovarian cancer cell lines, A2780 and cis-
platin-resistant A2780 (crA2780), respectively, with drug for 24 h
and followed the effects on cellular death and on the cell cycle
directly thereafter (day 1), in addition to the following two days
(Fig. 6). This allowed us to assess not only differences in how cells
are affected by but also recover from treatment.
Considering the profound cytotoxicity distinction of RAPTA-C
relative to RAED-C and cisplatin, we also quantiﬁed DNA
adducts after 24-h exposure of A2780 cells to different
concentrations of the three compounds (Fig. 2). Notably,
DNA–metal levels are closely linked to the respective cell growth
inhibiting power of the different agents. In particular, the amount
of DNA adducts measured for RAPTA-C, RAED-C and cisplatin
are approximately equal at their respective IC90 concentrations.
This implies that the effect of all three agents on cell killing and
growth inhibition arises primarily from the adducts formed on
DNA, and the cell cycle and death analyses were also performed
with the same degree and duration of treatment with compound.
To understand the magnitude and signiﬁcance of variations in
the cell death and cell cycle proﬁles, we used a multivariate
analysis method developed by Mahalanobis27. The Mahalanobis
distances designate levels of dissimilarity between any two
variable pairs, to which degrees of statistical conﬁdence can be
assigned. This analysis shows that the apoptosis and cell cycle
proﬁles between the control and cisplatin-, RAED-C- and
RAPTA-C-treated cells are highly distinct, with most of the
functionally relevant parameter pairs having P values o0.0001
(from the Fisher distances, n¼ 3; Supplementary Data 1).
In addition, the cell impact proﬁles for the three compounds
between the standard and resistant cell lines are distinct, while the
behaviour of the two types of control cells is very similar
(Supplementary Data 1I,J). This shows a differential impact of all
three agents on A2780 compared with crA2780 cells. However,
the relative differences, both in terms of apoptotic as well as cell
cycle arrest proﬁles, are much more pronounced for cisplatin
compared with either RAED-C or RAPTA-C. This is consistent
with the virtual lack of cross-reactivity with cisplatin for the
ruthenium compounds (see below).
Relative to cisplatin, which has a blatant and long-lasting effect
on cellular function, surviving cells recover more quickly after
RAED-C or RAPTA-C treatment (Fig. 6). Cisplatin-treated cells
display a jump in extent of apoptosis well above that seen for the
ruthenium agents 24 h (A2780 cells, day 2) or 48 h (crA2780 cells,
day 3) after drug removal, and RAPTA-C even shows a decrease
in apoptosis level by day 3, for A2780 cells (Fig. 6a and
Supplementary Data 1B,D). Moreover, cell cycle proﬁles for
RAED-C and RAPTA-C are more similar to control cells
subsequent to drug removal by day 2 or day 3 (Fig. 6b and
Supplementary Data 1F,H). Cisplatin is known to induce initial
S-phase arrest as a DNA replication blockade is encountered,
which is subsequently circumvented and followed later by
increased G2/M phase arrest corresponding to transcriptional
inhibition. In contrast, the ruthenium agents do not display this
signature and instead elicit a degree of S-phase and G2/M-phase
arrest that tends to diminish rapidly following drug removal
(Fig. 6b and Supplementary Data 1E–H).
Compared with the 14-fold cisplatin resistance level of the
crA2780 relative to the A2780 cells, RAED-C and RAPTA-C
display only a slight degree of cross-resistance, 1.5-fold and
2.1-fold, respectively (based on IC50 values, Table 2). Some low
level of cross-resistance seems also apparent in the fact that the
cell cycle impact of RAED-C and RAPTA-C, like cisplatin,
diminishes more rapidly following drug removal for the crA2780
compared with the A2780 cells (Fig. 6b and Supplementary Data
1F,H). On the other hand, whereas cisplatin relative to RAED-C
and RAPTA-C induces more rapid apoptosis in A2780 cells, the
impact potential is reversed in crA2780 cells, with RAED-C and
RAPTA-C appearing to induce a faster apoptotic response
(Fig. 6a and Supplementary Data 1A–D). Moreover, cisplatin
has a diminished capacity to induce S-phase arrest relative to
G2/M-phase arrest in the crA2780 compared with the A2780 cell
lines, and this pattern is in fact the opposite of what is seen
for RAED-C and RAPTA-C, which yield greater S-phase relative
to G2/M-phase arrest in the resistant cell line (Fig. 6b and
Supplementary Data 1E,G,J).
In addition to the pronounced distinctions relative to cisplatin,
differences in cellular impact between RAED-C and RAPTA-C
are also apparent. In particular, RAPTA-C is more effective than
RAED-C at inducing rapid G2/M-phase arrest (Fig. 6b and
Supplementary Data 1E–H).
Discussion
One potential advantage of existing metal-based anticancer agents
is that a given compound has the capacity to form adducts at
many different therapeutic sites, including targets foundational to
cell survival like DNA. This may permit superior efﬁcacy by
diminishing the likelihood of resistance gain. However, effective
design of improved drugs will depend on determining where
adducts are generated inside cells and which of the many adducts
that form are therapeutic versus counterproductive or ineffective.
This knowledge of site preference and mechanism of action
would allow one to selectively target weak points of cancer cells,
diminishing impact on healthy tissue.
Table 4 | Data collection and reﬁnement statistics for NCP
treated with RAED-C.
NCP–RAED-C
Data collection
Space group P212121
Cell dimensions
a (Å) 106.62
b (Å) 109.71
c (Å) 181.94
Resolution (Å) 2.69–60.6 (2.69–2.84)
Rmerge (%) 5.4 (48.7)
I/sI 18.5 (2.6)
Completeness (%) 93.1 (66.4)
Redundancy 6.8 (4.8)
Reﬁnement
Resolution (Å) 2.69–60.6
No. reﬂections 54,577
Rwork/Rfree (%) 24.8/28.2
No. atoms 12,093
Protein 6,078
DNA 5,939
Solvent 16
Adduct 60
B-factors (Å2) 84
Protein 57
DNA 112
Solvent 88
Adduct 163
r.m.s. deviations
Bond lengths (Å) 0.009
Bond angles () 1.43
NCP, nucleosome core particle; RAED-C, [(Z6-p-cymene)Ru(ethylenediamine)Cl]PF6;
r.m.s., root mean square.
Single-crystal data.
Values in parentheses are for the highest-resolution shell.
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Since they display low toxicity and favourable clearance
properties, in addition to non-cross-resistance attributes, ruthe-
nium agents have become promising alternatives to platinum
drugs5,6. Although RAED-C has been reported to display no
cross-resistance relative to cisplatin towards cisplatin-resistant
cancer cell lines17, we found here a slight level of cross-resistance
for both RAED-C and RAPTA-C. However, magnitude of cross-
resistance to different DNA-damaging agents has been shown to
depend critically on the extent to which cells are resistant
to cisplatin28. For instance, whereas (cr)A2780 cells that are
only 7.3-fold resistant to cisplatin are not cross-resistant to
adriamycin, those that are 14-fold resistant to cisplatin (an
identical level of resistance as the crA2780 cells used in our study)
display a 3.4-fold cross-resistance to this DNA intercalator.
Moreover, other compounds, such as the nitrogen mustard
alkylating agent melphalan, can display even greater levels of
differential cross-resistance between the less and more cisplatin-
resistant cell lines (2.1- versus 8.7-fold). In fact, the most
chemotherapy-resistant cell lines may provide superior models
for tumour biology, as these represent the most life-threatening
cell types. Therefore, the mere approximately twofold level of
cross-resistance found here for RAED-C and RAPTA-C with
respect to highly cisplatin-resistant cells is striking considering
that much greater degrees of cross-resistance are seen for
unrelated (non-metal-based) DNA-damaging agents. This is
encouraging since it suggests that the activity of ruthenium
agents has little overlap with the mechanisms that can protect
cancer cells from cisplatin and even other DNA-damaging
compounds.
Relative to RAPTA-C, which preferentially forms protein
adducts in the cell, the activity of RAED-C is overall more similar
to cisplatin, both in terms of DNA-targeting proclivity and
RAED-C
Histone
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RAPTA-C
DNA
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DNA
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0 kcal mol−1
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Figure 5 | Structure and energetics for the reaction of RAED-C and RAPTA-C at histone glutamate and DNA guanine sites in the nucleosome core.
The structures were extracted from QM/MM simulations performed on explicitly solvated NCP in the presence of the ruthenium agents. The relative
free energies (kcalmol 1) were calculated from constrained QM/MM simulations of the NCP by integrating the force acting along the reaction coordinate,
which corresponds to the developing coordinate-covalent bond between ruthenium and either a glutamate carboxylate oxygen or guanine N7 atom
(distances shown). H2O leaving groups are indicated with arrows.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4462
8 NATURE COMMUNICATIONS | 5:3462 |DOI: 10.1038/ncomms4462 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
apoptosis proﬁle (Fig. 6 and Supplementary Data 1A,C). This
supports the premise that RAED-C and cisplatin share high
cytotoxicity and antiprimary tumour activity by virtue of their
DNA lesion formation potential. However, the basal level of
cross-resistance and the distinct cellular impact between cisplatin
and RAED-C suggest that differences in DNA site preference and
adduct structure are consequential. In this regard, RAED-C
displays elevated DNA site selectivity over the classic platinum
drugs, which form adducts at essentially any solvent-exposed
guanine bases in the nucleosome core4. In contrast, RAED-C
tends to form adducts only at the most distorted regions within
the nucleosome core. Interestingly, in spite of this greater
discrimination, an even larger fraction of RAED-C that is taken
up by the cell ends up as DNA adducts, 6.4% (Table 1), compared
with 4.1% of cisplatin10. In addition, whereas the bifunctional
adducts of cisplatin cause extreme kinking of the double helix,
RAED-C produces monofunctional adducts that result in a much
more subtle distortion of the DNA. These conformational
differences in the double helix and distinctions in the steric
bulk of the adducts apparently underlie the lower nucleotide
excision repair efﬁciency observed for RAED-C relative to
cisplatin adducts in vitro20 and are also likely to yield
differential effects on transcription factor binding and
polymerase activity. Thus, there are substantial distinctions in
DNA-targeting potential as well as localization and structure of
the DNA adducts that form in the genome, which may account
for differences in impact on cell cycle and mode of cell death
between RAED-C and cisplatin by inﬂuencing adduct recognition
and repair.
One striking feature from the cellular studies is that both
standard and cisplatin-resistant cancer cells recover substantially
more quickly from RAPTA-C or RAED-C treatment compared
with cisplatin exposure. This is especially intriguing considering
that the cell treatment conditions yield roughly the same number
of initial DNA adducts (at day 1) for all three compounds.
Considering that the bonding strength of platinum is higher than
that of ruthenium compounds due to greater covalent character
of the adduct bonds would suggest that greater lability of the
ruthenium adducts allows these lesions to clear more quickly
subsequent to drug exposure. This may contribute to the
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Figure 6 | Impact of ruthenium agents and cisplatin on cell viability and function. (a) Apoptosis/necrosis proﬁles derived from ﬂow cytometric
analysis of cultured cells. (b) Cell cycle proﬁles based on ﬂow cytometric analysis of cultured cells. Day 1 measurements were made immediately
after switching cells to agent-free media (subsequent to 24 h incubation with agent), and day 2 and day 3 measurement correspond to cells residing
in agent-free media for an additional 1 or 2 days (mean±s.d., n¼ 3).
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favourable clearance and diminished toxicity properties of
ruthenium agents and consequently suggests that optimizing, as
opposed to maximizing, adduct stability may be a means for
achieving the greatest differential impact between cancer and
normal cells. In this sense, in conjunction with their elevated site
discrimination potential, ruthenium compounds may offer a
window of moderate-to-low cytotoxicity for cancer cell types or
contexts where the high toxicity/potency of platinum drugs is not
suited.
Metastasis is arguably the most serious challenge for anticancer
therapies, since it accounts for 90% of cancer deaths29. Unlike for
eradicating tumour cells, an effective antimetastasis agent need not
have cell-killing potential. In fact, a more readily achievable
compromise may be met by looking for non-toxic agents that
inhibit just the metastatic process itself, in particular since
metastatic cells are especially resistant to apoptosis making them
likely to be amongst the least affected by (nonspeciﬁc) cytotoxic
compounds30. In this regard, the properties so far displayed by
RAPTA-C are encouraging. In contrast to RAED-C, the low
cytotoxic potential of RAPTA-C is consistent with the very high
concentrations of the agent required to produce signiﬁcant levels of
DNA adducts. Changing the ethylenediamine ligand of
[Ru-cymene-Cl]þ to phosphaadamantane (þ Cl ) switches the
adduct formation proﬁle from primarily targeting the DNA to the
proteins associated with chromatin, and it is the sterically more
demanding phosphaadamantane group that is responsible for
inhibiting DNA adduct generation by increasing the reaction
activation barrier and destabilizing the adducted product. This
suggests new avenues to modulate DNA-targeting activity, and thus
cytotoxic potential, through conservative alterations in carrier
ligand structure. Nevertheless, in spite of the established distinctions
in molecular targeting, it is possible that the mono-versus-
bifunctional difference in coordination ability between RAED-C
and RAPTA-C also contributes to their differential activity proﬁles.
In this sense, RAPTA-C has the potential to form cross-links in and
between proteins and nucleic acids, and whether such bonding is of
functional signiﬁcance remains to be determined.
Although the mechanism behind the antimetastasis activity of
RAPTA-C is not yet clear, it appears that protein targets are most
probably involved. Since RAPTA-C has a particular proclivity to
accumulate adducts at chromatin-associated proteins, it is
interesting to speculate that histone lesions may contribute to
the efﬁcacy of this agent. The distinct proﬁle of RAPTA-C for
inducing rapid G2/M-phase arrest could be associated with such
binding activity and suggests possibilities for novel combination
anticancer therapies employing both histone- and DNA-targeting
compounds. However, since almost 96% of the RAPTA-C
adducts that form inside the cell are at non-chromatin sites,
additional protein targets may well be relevant.
The traditional deﬁnition of the cancerous state as arising from
purely genetic abnormalities is now amended to entail epigenetic
changes as critical elements in the oncogenic process31,32.
Thus, cancer cells can be characterized by numerous, yet gene-
speciﬁc, structural and chemical abnormalities in chromatin, which
include distinctions in chromatin compaction status, nucleosome
organization, DNA methylation, histone variant composition and
post-translational modiﬁcation of histones. In fact, recent work
shows that subpopulations of drug-resistant cancer cells are even
established via epigenetic modiﬁcations of chromatin33. The ability
of RAPTA-C and RAED-C to recognize not just chemical but
structural features of nucleosomes holds promise for targeting
epigenetic weak points of cancer cells and suggests that these
ruthenium agents and other compounds may achieve their
therapeutic effects serendipitously through such activity. For
instance, RAED-C adduct formation is dependent on double helix
distortions in the nucleosome core and could thus be sensitive to
differences in nucleosome positioning in the genome. Moreover, a
remarkable feature of RAPTA-C is that it preferentially forms
adducts at histone protein sites residing on the surface of the
nucleosome core8. These include regions known to be important in
chromatin compaction and protein factor association that are key
transactions in gene regulation and cell division. As such, adduct
formation at these histone regulatory sites could be sensitive to
histone composition and compaction status of nucleosomes.
Further characterization of the epigenetic vulnerabilities of cancer
cells with improved understanding of metallocompound targeting
and mode of action should yield superior drugs.
Methods
Ruthenium compound synthesis. RAPTA-C and RAED-C were synthesized as
described previously12,16. In brief, for the synthesis of RAPTA-C, equimolar
amounts of 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane and [Ru(Z6-p-
cymene)Cl2]2 were reﬂuxed in methanol, and the product was precipitated by
addition of diethyl ether. RAED-C was prepared by stirring the methanol solution
of [Ru(Z6-p-cymene)Cl2]2 with an excess of ethylenediamine. Pure crystalline
product was obtained by addition of NH4PF6 and reducing the volume to 75–90%.
The purity of the prepared products was conﬁrmed through elemental analysis.
Cellular uptake experiments. Human A2780 ovarian carcinoma cells were
obtained from the European Centre of Cell Cultures (Salisbury, UK) and
maintained in culture as described by the provider. The cells were grown at 37 C
and 5% CO2 in RPMI 1640 medium containing 10% FCS with 2mM glutamine,
100 unitsml 1 penicillin and 100mgml 1 streptomycin.
The A2780 cells were seeded in six-well plates, grown toB50% conﬂuency and
incubated with RAED-C or RAPTA-C at concentrations of 5 mM or 250mM
(corresponding to their IC50 values; Table 2), respectively, for 24 h at 37 C. At the
end of the incubation period, the cells were washed three times with ice-cold PBS
before being detached using an enzyme-free dissociation solution (Millipore,
Switzerland). The cells were then centrifuged for 5min at 700g and 4 C and
washed twice with ice-cold PBS. Cell lysis was achieved using a freeze-thaw
technique that was recently found to be suitable for cell uptake studies34. All
samples were analysed for their protein content before ICP-MS determination
using a bicinchoninic acid assay (Sigma-Aldrich, Switzerland).
Chromatin isolation. Chromatin isolation was achieved with a Pierce Chromatin
Prep Module (26158; Thermo Scientiﬁc, Switzerland). Cells were grown in 75 cm2
ﬂasks toB80% conﬂuence before being incubated for 24 h at 37 C with RAED-C
or RAPTA-C at concentrations of 5 mM or 250 mM, respectively. At the end of the
incubation period, cells were washed three times with ice-cold PBS to remove
unbound drug, and the chromatin extract was prepared in accordance with the
protocol supplied by the manufacturer. The determination was carried out as three
independent experiments.
DNA isolation. Isolation of genomic DNA was carried out using a GenElute
Mammalian Genomic DNA Miniprep Kit (G1N70; Sigma-Aldrich, USA). For the
measurements in Table 1, cells were grown in 25 cm2 ﬂasks to B80% conﬂuency
before being incubated with RAED-C or RAPTA-C at concentrations of 5 mM or
250 mM, respectively, for 24 h at 37 C. For the measurements in Fig. 2, cells
(obtained from the Health Protection Agency Culture Collections, Salisbury, UK)
were grown in 60mm plates to B90% conﬂuency before being incubated with
3/10/20 mM RAED-C, 247/772/1493 mM RAPTA-C or 2/10/20 mM cisplatin for
24 h at 37 C. The amount of DNA was quantiﬁed by ultraviolet absorption
measurements at 260 nm and subjected to ICP-MS analysis.
Determination of binding constants. X-ray crystallographic, DNA footprinting
and analytical analysis of NCP and corresponding naked DNA were conducted
using a 145-bp DNA fragment and nucleosome assembled with recombinant
histones23. Samples containing 20mM K-cacodylate (pH 6.0), 5 mM NCP and
RAED-C:NCP ratios of 1:1, 2:1, 4:1 and 10:1 were incubated at room temperature
for up to 48 h. Kinetic experiments of samples containing a 2:1 RAED-C:NCP ratio
were carried out to determine the rate constant of the binding reaction (by
monitoring the NCP–RAED-C adduct peak area) and the time required for an
equilibrium to be established. The rate constant k was determined assuming
pseudo-ﬁrst-order kinetics and the binding constant K by using the equation
r¼ (nKc)/(1þKc) (r, bound drug:NCP molar ratio; n, number of binding sites;
c, concentration of unbound drug)35. The equation was solved for different
RAED-C:NCP ratios by nonlinear regression analysis using Polymath 6.1. To assess
the distribution of RAED-C adducts between the histone proteins and DNA of the
nucleosome core, RAED-C-treated NCP was ﬁrst dissociated with the addition of
NaCl to a ﬁnal concentration of 2.5M before size exclusion chromatography (SEC)
fractionation.
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ICP-MS measurements. All determinations of metal content were conducted by
monitoring the 102Ru signal on an Elan DRC II ICP-MS instrument (Perkin Elmer,
Switzerland) equipped with a Meinhard nebulizer and a cyclonic spray chamber or
a 7700x Agilent ICP-MS instrument (Agilent Technologies, CA, USA) equipped
with a MicroMist glass concentric nebulizer and a quartz Peltier-cooled spray
chamber. For determination of the ruthenium or platinum content in the
chromatin or DNA extracts, all samples were digested in concentrated ultrapure
nitric acid (Sigma-Aldrich, Switzerland) for 3 h and the ﬁnal volume adjusted with
the addition of ultrapure water. Indium was added at a concentration of 0.5 p.p.b.
as an internal standard. For SEC-ICP-MS measurements, a Perkin Elmer Series
200 HPLC-system was directly coupled to the Elan DRC II instrument. Twenty
microlitres of sample was injected, and separations were achieved on a TSKGel SW
guard column (Tosoh Biosciences, Germany) at a ﬂow rate of 0.8mlmin 1 using
100mM ammonium acetate running buffer.
The ICP-MS instrument was tuned using a solution provided by the
manufacturer containing 1 p.p.b. each of Mg, In, Ce, Ba, Pb and U. External
standards were prepared gravimetrically in identical matrix to the samples
(with regard to internal standard and nitric acid) with single element standards
obtained from CPI International (Amsterdam, The Netherlands). The SEC
columns were calibrated using a molecular weight calibration mixture with a
range of 5–700 kDa (Sigma-Aldrich, Switzerland).
DNA footprinting analysis. Exonuclease III footprinting experiments for
obtaining RAED-C and RAPTA-C adduct formation proﬁles, based on digest
(30–50 direction) termination at DNA lesion sites, were conducted in a similar
manner as described previously for platinum adduct mapping4,21. Five micromolar
naked DNA or NCP in a buffer of 20mM K-cacodylate (pH 6.0) was incubated at
room temperature for 24 h with a 10-fold molar excess, for naked DNA, or a
20-fold molar excess, for NCP, of RAED-C or RAPTA-C. Samples were treated by
heating at 55 C with the addition of 4M NaCl to a ﬁnal concentration of 2M,
followed by phenol-chloroform extraction and ethanol precipitation of the DNA,
which was then 50-end-labelled (32P) with polynucleotide kinase. Six hundred and
seventy-ﬁve nanograms of DNA samples were subjected to digestion with 250 units
of exonuclease III for 1 h, which is a 10-fold excess over that minimally required for
full digestion of the untreated DNA. After ethanol precipitation, digested DNA
samples were subsequently stripped of ruthenium adducts by treatment with 1M
thiourea for 16 h at 58 C, followed again by ethanol precipitation of the DNA.
Modiﬁed Maxam–Gilbert purine sequencing standards were prepared initially
as described36, whereby DNA was 50-end-labelled (32P) with polynucleotide kinase,
followed by treatment of 10ml of the DNA (B100mgml 1) with 25ml of 80% (v/v)
formic acid. The reaction was halted after an incubation of 4–8min by addition of
200ml stop buffer (0.3M Na-Acetate, 0.1 M EDTA, 25 mgml 1 RNA), followed
immediately by addition of 750 ml cold ethanol. After 10min incubation on ice, the
DNA was pelleted by centrifugation. The DNA pellet was then dissolved in 200 ml
of 10% (v/v) piperidine, and the sample was incubated at 95 C. The reaction was
stopped after 45min by ethanol precipitation of the DNA. Finally, DNA markers
were subjected to 30-dephosphorylation by treatment with 1 unit of polynucleotide
kinase per 20 ng DNA for 16 h. The ethanol precipitated DNA marker pellet was
resuspended by the addition of B10ml of loading dye and heating at 95 C for
3min. All DNA fragments were resolved by denaturing polyacrylamide gel
electrophoresis (10% polyacrylamide, 8M urea, 45mM Tris-borate, 1mM EDTA,
pH 8.3), in which loaded quantities of ruthenium agent-treated DNA samples
corresponded to approximately equal total radioactive counts visible on the gel.
Crystallographic analysis of treated NCP. NCP crystals were produced and
stabilized in harvest buffer (37mM MnCl2, 40mM KCl, 20mM K-cacodylate
(pH 6.0), 24% 2-methyl-2,4-pentanediol and 2% trehalose) as previously
described37. The 37-mM MnCl2 buffer component was subsequently eliminated by
gradual replacement with 10mM MgSO4 followed by thorough rinsing of crystals
with the MgSO4-containing buffer to remove any residual MnCl2 (ref. 8). The
NCP–RAED-C crystal structure reported here stems from a 21-h incubation of
NCP crystals with 1mM RAED-C included in the buffer.
Single-crystal X-ray diffraction data were recorded, with crystals mounted
directly into the cryocooling N2 gas stream set at  175 C, at beam line X06DA of
the Swiss Light Source (Paul Scherrer Institute, Villigen, Switzerland) using a
Mar225 charge-coupled device (CCD) detector and an X-ray wavelength of 1.50Å.
Data were processed with MOSFLM38 and SCALA from the CCP4 package39.
The native NCP145 and NCP-TA2 models (pdb codes 3REH and 3UTA)4,25
were used for initial structure solution by molecular replacement. Structural
reﬁnement and model building were carried out with routines from the CCP4
suite39. Restraint parameters for the adducts were based on the small molecule
crystal structure of RAED-C16. Data collection and structure reﬁnement statistics
are given in Table 4. Graphic ﬁgures were prepared with PyMOL (DeLano
Scientiﬁc LLC, San Carlos, CA, USA).
Computational investigations. We based our molecular dynamics (MD) simu-
lations on the 2.5-Å resolution crystal structure of NCP (PDB code 3REH)4. We
built four models using this structure as a reference, which differ in the site (DNA
versus protein) in which the hydrolysed Ru drugs (RAED-C or RAPTA-C) were
docked. Each model was immersed in a periodic box of B130 97 133Å3
containing about 48,300 water molecules neutralized with Naþ counterions. The
box dimensions were chosen to achieve a minimum distance of 28Å between two
periodically replicated images of the system. The ff10 parameterization of the
all-atom AMBER force ﬁeld40–43 was used to model protein residues, nucleic acids
and counterions, whereas the TIP3P model44 was employed for water molecules.
Non-standard force ﬁeld parameters for Ru drugs were taken from previous
studies45. Electrostatic interactions were taken into account using the Particle Mesh
Ewald algorithm46 with a real-space cutoff of 12Å. The same cutoff was employed
for the treatment of the van der Waals interactions. An integration time step of 1 fs
was used. Constant temperature (310 K) simulations were achieved by coupling the
system to a Langevin thermostat. After initial minimization, systems were heated
up to 310K over 620 ps, while imposing positional restraints on the heavy atoms.
Subsequently, restraints were slowly removed and 50 ns of unrestrained dynamics
in the NVT ensemble were performed for each simulation to provide starting
conﬁgurations for the following QM/MM runs. All the classical MD simulations
were carried out using the NAMD package47.
Four QM/MM MD simulations, one for each of the models equilibrated as
mentioned above, were performed. Conﬁgurations in which the distance, d,
between the Ru atom of RAPTA-C/RAED-C and the nucleophilic atom of the
DNA site or histone site was B8Å were chosen to start the different QM/MM
runs. The QM/MM implementation employed combines the use of the QM
program QUICKSTEP48 and the MM driver FIST, both part of the CP2K package
(freely available at the URL http://www.cp2k.berlios.de, released under GPL
licence). In this code, the general QM/MM scheme is based on a real-space
multigrid technique to compute the electrostatic coupling between both QM and
MM regions49,50. In all the simulations, a quantum region consisting of the Ru
compound and either the guanine base (truncation at the N9 atom) or the
glutamate side chain (truncation at the Cb atom) was treated at the density
functional theory level. The remaining part of the system, including water
molecules and counterions, was modelled at the classical level using the AMBER
force ﬁeld to take into account explicitly the steric and electrostatic effects of the
macromolecular environment and solvent. The valence of the terminal QM atoms
was saturated by the addition of capping hydrogen atoms, and a dual basis set,
Gaussian and plane-wave formalism, was employed to compute the interaction
energy within the QM subsystem. A molecularly optimized double-zeta valence
basis set augmented with polarization functions (m-DZVP) was used51 to describe
the wave function, while an auxiliary plane-wave basis set expanded up to a density
cutoff of 320 Ry was utilized to converge the electron density in conjunction with
Goedecker–Teter–Hutter pseudopotentials52,53 to describe the core electrons.
Exchange and correlation energies were computed within the generalized gradient
approximation by using the Perdew-Burke-Ernzerhof functional54.
All the ab initio MD simulations were performed with Born–Oppenheimer MD
in the canonical (NVT) ensemble and using an integration time step of 0.5 fs. The
QM region of each of the QM/MM structures was initially relaxed by performing a
geometry optimization while the MM part was kept frozen. Then the systems were
thermalized and further equilibrated for about 2 ps by using a stochastic velocity
rescaling thermostat55 to maintain the temperature at 310 K. Snapshots extracted
from these runs were used as starting conﬁgurations to estimate the free energy
proﬁles corresponding to adduct formation on the DNA and histone sites for both
Ru drugs. These free energy proﬁles were determined by integrating the constraint
force acting along the distance d chosen as reaction coordinate56. For each value of
the reaction coordinate, every system was run for 6–8 ps. Average forces were
computed from data collected over the last 5 ps of those trajectories.
Full QM calculations on model systems were carried out using the Gaussian09
suite of programmes57. Geometry optimizations were performed with the B3LYP
density functional method58 by using the relativistic effective core pseudopotential
LANL2DZ for ruthenium and the 6-31þG* basis set for the remaining atoms59.
To take into account condensed-phase effects, we used a united atom applied on
radii optimized for Hartree-Fock [6-31G(d) level] polarizable continuum model
with a relative permittivity of 78.3 to simulate bulk water effects60,61.
Determination of cell growth inhibition parameters. Human ovarian carcinoma
cell lines, A2780 and crA2780, were purchased from the Health Protection Agency
Culture Collections and maintained in culture as described above, with crA2780
cells additionally treated with 1 mM cisplatin for every 2–3 passages to maintain
resistance. Cisplatin was purchased from Sigma-Aldrich, USA (P4394-250MG).
To measure the cytotoxicity from exposure to different agents, cells were seeded
in 96-well plates (5,000 cells per well) and grown for 24 h. Stock solutions of
cisplatin, RAED-C, RAPTA-C were prepared in complete medium, subjected to
serial dilutions and then added to the cells at various concentrations. Following a
72-h incubation, media were aspirated and 100 ml of 10% 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide in RPMI complete medium (TOX1-1KT;
MTT kit, Sigma-Aldrich, USA) was added to cells, which were incubated for 3 h at
37 C. Subsequently, 100ml of solubilization buffer was added to each well with
vigorous pipetting to dissolve formazan. The resulting optical density was
measured at 570 and 690 nm using a multi-well plate reader (Inﬁnite M200 PRO,
Magellan data analysis software; TECAN, Switzerland). The ratios of surviving cells
were calculated by comparing with the untreated samples, and the IC50 and IC90
were derived based on three data sets (see Table 2).
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Cellular death and cell cycle analyses. Cells were seeded into 35mm-wells,
incubated overnight and the following day cisplatin, RAED-C and RAPTA-C, were
added into triplicate samples for 24 h incubations at concentrations corresponding
to the IC90 values. Subsequently, the media containing drugs was removed and
fresh media was added. The cells were collected for analysis immediately (day 1)
and subsequent to further 24 h (day 2) and 48 h (day 3) incubations in drug-free
media.
Extent of apoptosis/necrosis was assessed using an Annexin-V-FLUOS staining
kit (11988549001; Roche Diagnostics, Germany). Floating cells as well as attached
cells were collected, washed in PBS and stained with Annexin V and propidium
iodide. Cells were then incubated for 15min in the dark and analysed on an LSR II
ﬂow cytometer (BD FACSDiva software, BD Biosciences).
For the cell cycle analysis, cells were rinsed in PBS, trypsinized, pelleted and
washed before they were added in a drop-wise manner into 70% ethanol. After
overnight incubation, cells were washed in PBS and incubated with 40 ,6-diamidino-
2-phenylindole dihydrochloride (3 mM, Life Technologies) for 15min in the dark
before analysing on an LSR II ﬂow cytometer (BD FACSDiva software, BD
Biosciences).
Analysis of cellular data was based on three independent replicates of each
experiment. Graphic plots were generated with Excel (Microsoft Corporation).
Mahalanobis multivariate analysis was carried out using Xlstat (version 2013.1.01;
Addinsoft Corporation).
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